home / lobbying

lobbying_activities

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

1,146 rows where filing_year = 2023 and issue_code = "PHA" sorted by filing_year descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: filing_type, is_termination, received_date (date)

filing_period 4

  • third_quarter 293
  • fourth_quarter 290
  • second_quarter 284
  • first_quarter 279

issue_code 1

  • PHA · 1,146 ✖

filing_year 1

  • 2023 · 1,146 ✖
id filing_uuid filing_type registrant_name registrant_id client_name filing_year ▲ filing_period issue_code specific_issues government_entities income_amount expense_amount is_no_activity is_termination received_date
2954246 STONINGTON GLOBAL da7482bf-a22f-45da-a22c-069b85f2b3b0 Q1 STONINGTON GLOBAL 401105189 SORRENTO THERAPEUTICS, INC. 2023 first_quarter PHA Promoting non-opioid pain management alternatives. Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office 60000   0 0 2023-03-27T11:04:21-04:00
2954260 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING aea743c8-defe-4380-837f-2803c8dd186f Q1 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 35968 SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING 2023 first_quarter PHA HR 1199, FIND Act, radiopharmaceutical reimbursement HOUSE OF REPRESENTATIVES,SENATE   70000 0 0 2023-03-27T18:31:23-04:00
2954566 PENN AVENUE PARTNERS edd30bec-25a3-47da-bca3-91f70905f320 Q1 PENN AVENUE PARTNERS 400918672 ALKERMES, INC. 2023 first_quarter PHA Regulatory and legislative issues impacting Alkermes. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-04-03T11:42:24-04:00
2954637 PENN AVENUE PARTNERS 0fad7689-1389-4f5c-a5c2-6f49ab6ea036 Q1 PENN AVENUE PARTNERS 400918672 UNITEDHEALTH GROUP, INC. 2023 first_quarter PHA Pharmacy benefit related issues. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE,White House Office 90000   0 0 2023-04-03T13:26:36-04:00
2955051 WATKINS & EAGER PLLC 672115f8-d2e2-48d6-94e4-a4aacb87926b Q1 WATKINS & EAGER PLLC 401104403 ZYNERBA PHARMACEUTICALS, INC. 2023 first_quarter PHA Encourage Members to act favorably on matters of importance to Zynerba at their direction; Trial for medication that could help individuals with Fragile X Syndrome. HOUSE OF REPRESENTATIVES,SENATE 15000   0 0 2023-04-05T11:19:18-04:00
2955119 AMERICAN COLLEGE OF CLINICAL PHARMACY fee4884b-f8ab-4153-b647-dc455ca8969f Q1 AMERICAN COLLEGE OF CLINICAL PHARMACY 57258 AMERICAN COLLEGE OF CLINICAL PHARMACY 2023 first_quarter PHA Coverage for direct patient care services of qualified clinical pharmacists under Medicare and other public health programs. HOUSE OF REPRESENTATIVES,SENATE   144981 0 0 2023-04-05T13:39:08-04:00
2955473 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 4f9b018f-59fb-48ae-a40c-4137c0d71781 Q1 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 401103605 PHARMA & BIOPHARMA OUTSOURCING ASSOCIATION 2023 first_quarter PHA Discussed issues related to drug shortages, pandemic preparedness, workforce development, advanced manufacturing, and onshoring HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2023-04-06T12:45:53-04:00
2955589 REPUBLIC CONSULTING, LLC 5f565610-696f-4b2e-988f-4026cd1f26e9 Q1 REPUBLIC CONSULTING, LLC 401016871 IQVIA 2023 first_quarter PHA Monitor Health Data Policy. Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-06T15:41:57-04:00
2955845 INDEPENDENT PHARMACY COOPERATIVE f83017be-ac3e-480a-8432-c0a783306612 Q1 INDEPENDENT PHARMACY COOPERATIVE 313098 INDEPENDENT PHARMACY COOPERATIVE 2023 first_quarter PHA IPC supports S.127 Pharmacy Benefit Manager Transparency Act of 2023. IPC supports S.113 Prescription Pricing for the People Act of 2023. IPC supports H.R. 1770 Equitable Community Access to Pharmacists Services Act of 2023. IPC supports the Inflation Reduction Act of 2022 and CMS implementation. IPC supports H.R. 1613 Drug Price Transparency in Medicaid Act of 2023. Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE   30000 0 0 2023-04-07T13:12:41-04:00
2956346 LUNGREN LOPINA LLC f69f5935-5f04-4d76-9479-ac68f02e4584 Q1 LUNGREN LOPINA LLC 401103314 AMPAC FINE CHEMICALS 2023 first_quarter PHA Fair treatment for US based pharmaceutical ingredients Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-04-10T12:36:50-04:00
2956605 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 54d7ebcb-1d3d-4208-af99-ba8c6b5e1360 Q1 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 11003 COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE 2023 first_quarter PHA CCAGW Urges Senate Judiciary Committee to Oppose S. 150 SENATE   310000 0 0 2023-04-10T15:46:12-04:00
2956890 MCDERMOTT+ LLC 391b453c-19cf-439a-9210-b728de831a4a Q1 MCDERMOTT+ LLC 401103287 ALLIANCE FOR RURAL HOSPITAL ACCESS 2023 first_quarter PHA Amendments to Section 340B of the Public Health Service Act regarding eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-11T11:07:26-04:00
2957069 PANNONE LOPES DEVEREAUX & O'GARA LLC d563b0bd-3ac1-4ea5-b95e-2a91384c67c6 Q1 PANNONE LOPES DEVEREAUX & O'GARA LLC 401105501 AMGEN 2023 first_quarter PHA Prescription drug pricing.   9000   0 0 2023-04-11T13:08:49-04:00
2957220 UC HEALTH 88cf6ec4-1deb-4267-a973-94b7dec6b6af Q1 UC HEALTH 401103195 UC HEALTH 2023 first_quarter PHA 340B HOUSE OF REPRESENTATIVES,SENATE   37500 0 0 2023-04-11T15:09:16-04:00
2957264 RED+BLUE STRATEGIES a25220b8-283b-4f1c-99d6-5ea9eb4de71d Q1 RED+BLUE STRATEGIES 400693064 PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA) 2023 first_quarter PHA S. 127 - The PBM Transparency Act - Issues related to the study of Pharmacy Benefit Managers by the Federal Trade Commission. S. 150 - Affordable Prescriptions for Patients Act - Issues related to ensuring that people's access to affordable medications are not impeded and innovations to ensure fair pricing structures are promulgated to their fullest. Issues related to prescription drug supply chain integrity and transparency. Issues related to the implementation of the Inflation Reduction Act for purposes of ensuring access to affordable medications for Medicare beneficiaries and people across the United States. Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2023-04-11T15:37:56-04:00
2957571 PARDES BIOSCIENCES, INC. 1a12c753-97e8-4a54-a861-d35307ae0862 Q1 PARDES BIOSCIENCES, INC. 401106493 PARDES BIOSCIENCES, INC. 2023 first_quarter PHA Physician prescribing of covid antivirals Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE   120000 0 0 2023-04-12T10:25:50-04:00
2957575 PARDES BIOSCIENCES, INC. 7b178cfd-76ff-4ab0-bfa0-f3bee1a34931 2T PARDES BIOSCIENCES, INC. 401106493 PARDES BIOSCIENCES, INC. 2023 second_quarter PHA Physician prescribing of covid antivirals Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,Office of Science & Technology Policy (OSTP),SENATE   120000 0 1 2023-04-12T10:26:43-04:00
2957599 AMERICAN VETERINARY MEDICAL ASSOCIATION 3d3cb78b-2833-4844-a62f-b548d577d887 Q1 AMERICAN VETERINARY MEDICAL ASSOCIATION 3630 AMERICAN VETERINARY MEDICAL ASSOCIATION 2023 first_quarter PHA Compounding Guidance (GFI 256) H.R. 1418 Animal Drug User Fee Act/ Animal Generic Drug User Fee Act reauthorization H.R. 1839/S. 993 Combatting Illicit Xylazine Act Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   330000 0 0 2023-04-12T10:49:30-04:00
2957786 HOLLAND & KNIGHT LLP 502f262d-1d08-42b5-a839-090dec11baa3 Q1 HOLLAND & KNIGHT LLP 18466 VIATRIS INC 2023 first_quarter PHA Increasing Transparency in Generic Drug Applications Act, (S. 775), Part D Formulary Design; Supply Chain Issues, E-labeling; Inflation Reduction Act Implementation, Improving Generic Drug Access, PEPFAR. Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-12T13:57:13-04:00
2958423 NELSON MULLINS RILEY & SCARBOROUGH 71611910-7a9e-47be-b7fb-aab9ebae4354 Q1 NELSON MULLINS RILEY & SCARBOROUGH 285871 TIDELANDS HEALTH 2023 first_quarter PHA Issues related to the 340B Drug Pricing Program SENATE 40000   0 0 2023-04-13T11:12:29-04:00
2958566 NELSON MULLINS RILEY & SCARBOROUGH f8687de3-c0f1-4610-8fa8-08486bfdc2d3 Q1 NELSON MULLINS RILEY & SCARBOROUGH 285871 HEMOPHILIA OF GEORGIA 2023 first_quarter PHA 340B Drug Pricing Program, patient co-pays legislation (H.R. 830) HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-04-13T12:31:58-04:00
2958568 HOGAN LOVELLS US LLP 5e08d0d6-ba92-4667-891c-0c2ecedac04b Q1 HOGAN LOVELLS US LLP 18422 ALVOGEN, PHARMA US, INC. 2023 first_quarter PHA Issues related to COVID-19 HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-04-13T12:33:37-04:00
2958742 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 5e04a25c-271f-4a98-aea4-77b409b5eeca 1A CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 29403 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2023 first_quarter PHA OTC Switch - general advocacy on Prescription to Over-the-Counter Switch of medications and ingredients. The Wastewater Infrastructure Pollution Prevention and Environmental Safety Act or the WIPPES Act -- not yet introduced. Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 148265   0 0 2023-04-13T14:37:59-04:00
2959033 ARNOLD & PORTER KAYE SCHOLER LLP 1bb358dd-c662-4d25-b96b-e0e8c0aa926c Q1 ARNOLD & PORTER KAYE SCHOLER LLP 4301 PERRIGO COMPANY PLC 2023 first_quarter PHA Issues related to over-the-counter birth control. HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-04-14T01:43:56-04:00
2959078 AARP 39aa04f7-e991-42f1-a3b9-beb034ed1208 Q1 AARP 1694 AARP 2023 first_quarter PHA S.79, Interagency Patent Coordination and Improvement Act of 2023. S.113, Prescription Pricing for the People Act of 2023. S.142, Preserve Access to Affordable Generics and Biosimilars Act of 2023. S.148, Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics Act or the Stop (STALLING) Act. S.150, Affordable Prescriptions for Patients Act of 2023. S.935, the Fair Accountability and Innovative Research (FAIR) Drug Pricing Act of 2023. No bill number. Discussed Medicare prescription drug inflation rebate program. No bill number. Discussed proposed Advance Notice of Methodological Changes for Calendar Year (CY) 2024 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies. No bill number. Discussed proposed Contract Year 2024 Policy and Technical Changes to the Medicare Advantage (MA) and Medicare Prescription Drug Benefit Program (Part D). H.R.485, Protecting Health Care for All Patients Act of 2023. No bill number. Discussed Drug-Price Transparency for Consumers (DTC) Act of 2023. No bill number. Discussed Biosimilar Red Tape Elimination Act. No bill number. Discussed Protecting Consumer Access to Generic Drugs Act. No bill number. Discussed federal prescription drug pricing. No bill number. Discussed insulin prices. No bill number. Discussed out of pocket cost smoothing in Part D. No bill number. Discussed prescription drug access and prices. Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office   3850000 0 0 2023-04-14T08:31:06-04:00
2959207 KOUNTOUPES DENHAM CARR & REID, LLC 16b02461-d413-4a83-ad3e-58c6677f4e2c 1T KOUNTOUPES DENHAM CARR & REID, LLC 320918 ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN) 2023 first_quarter PHA Issues related to generic pharmaceuticals and biosimilars, including reimbursement rate, pricing and supply chain. HOUSE OF REPRESENTATIVES,SENATE 20000   0 1 2023-04-14T09:56:34-04:00
2959267 DAVE KOLBE CONSULTING 9f87c7ae-eaa1-4970-9324-8baee32e8d00 Q1 DAVE KOLBE CONSULTING 401104329 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2023 first_quarter PHA S. 113 Prescription Pricing for the People Act of 2023 S. 127 Pharmacy Benefit Manager Transparency Act of 2023 As a result of their impact on the prices charged to the patient or sponsor, many of the contractual and billing practices of the non-manufacturer links in the drug supply chain provide unnecessary barriers to receiving access to needed prescription drugs. Among others, these impact the participants, dependents, beneficiaries and survivors who receive their health benefits from jointly managed, multiemployer health benefit plans. These realities are in direct conflict with the stated policy positions of PILMA. The proposed Senate bills, S. 113 and S. 127 are both steps in the right direction although modifications and additional provisions that would strengthen the legislation. SENATE 30000   0 0 2023-04-14T10:27:32-04:00
2959397 ALB SOLUTIONS a951fe7d-a3bc-465f-893b-82bbbb1b7a51 Q1 ALB SOLUTIONS 401105973 BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2023 first_quarter PHA Issues related to regulatory and legislative developments regarding biosimilars. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-04-14T12:12:15-04:00
2960627 BROYDRICK & ASSOCIATES 47526e90-2fbe-47fe-b58b-4e50f0dec912 Q1 BROYDRICK & ASSOCIATES 7268 TONIX PHARMACEUTICALS 2023 first_quarter PHA Funding for drug treatment for PTSD and COVID-19, BARDA appropriations. Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-04-17T09:48:20-04:00
2960755 LINCOLN PARK GROUP L.L.C. b8c87ae2-8ed9-4f2c-8467-c41775cc7611 Q1 LINCOLN PARK GROUP L.L.C. 401104374 CANADIAN INTERNATIONAL PHARMACY ASSOCIATION 2023 first_quarter PHA Issues related to importation of medicines for personal use. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-04-17T10:24:19-04:00
2960861 THE CONSILIO GROUP d24787c8-ca30-48d3-a80f-0491ca1a5b97 Q1 THE CONSILIO GROUP 400374717 PARATEK PHARMACEUTICALS 2023 first_quarter PHA Development and commercialization of novel life-saving therapies for life-threatening diseases and other public health threats for civilian, government, and military use Air Force, Dept of,Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,SENATE,U.S. Secret Service,White House Office 36000   0 0 2023-04-17T10:50:49-04:00
2961049 EMERGENT STRATEGIES 0edef954-e4af-4d10-b6bf-1c20fc14129f Q1 EMERGENT STRATEGIES 401104778 GENBIOPRO, INC. 2023 first_quarter PHA FDA Approval of generic mifepristone and related Risk Evaluation Mitigation Strategies (REMS). Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE 35000   0 0 2023-04-17T11:17:03-04:00
2961219 FORBES-TATE 1fff84e1-8e6f-4804-b36a-40759a34f5fa Q1 FORBES-TATE 400976792 INDEPENDENT PHARMACY COOPERATIVE 2023 first_quarter PHA Issues related to pharmacy regulation, Provider Status, opioid addiction, drug pricing, and Pharmacy Benefit Manager transparency. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-17T11:48:28-04:00
2961259 FORBES-TATE ba81b86f-1295-41e4-a223-e0db04fda87c Q1 FORBES-TATE 400976792 CALIFORNIA LIFE SCIENCES ASSOCIATION 2023 first_quarter PHA Issues related to the life sciences industry; Issues related to drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022(P.L. 117-169). HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-04-17T11:54:08-04:00
2961456 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 2870aac4-a7f1-485b-96ff-2bea3c9380e6 Q1 KEEFE STRATEGIES LLC (FKA KEEFE SINGISER PARTNERS) 401105192 CVS HEALTH 2023 first_quarter PHA Issues encompassing general education regarding the pharmacy benefit manager/pharmacy industry. Issues related to access and affordability of healthcare, prescription drugs, and generic drugs. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-17T12:27:24-04:00
2962431 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION d78af6fd-213f-4209-9cb3-b1413faf9609 Q1 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 27478 NATIONAL COMMUNITY PHARMACISTS ASSOCIATION 2023 first_quarter PHA H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 382, the Pandemic is Over Act; Draft legislation, Drug Shortage Protection Act; Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   370000 0 0 2023-04-17T16:21:23-04:00
2962763 BROWNSTEIN HYATT FARBER SCHRECK, LLP 339b49eb-dcb0-48a4-a796-68369753d0c4 Q1 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 WALGREEN CO. 2023 first_quarter PHA Pharmacist provider status Pharmacy benefits on military bases Issues related to drug pricing Issues related to COVID-19 relief Inflation Reduction Act of 2022 INFORM Act Issues related to access and distribution of pharmaceutical products HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-17T17:48:31-04:00
2962802 GOVERNMENT COUNSEL, LLC 99b60aba-9bfc-4737-bdc1-717baefad4bc Q1 GOVERNMENT COUNSEL, LLC 401105070 HEALTHCARE DISTRIBUTION ALLIANCE 2023 first_quarter PHA H.R. 501-Block, Report, And Suspend Suspicious Shipments Act; General issues relating access to medication assisted treatment. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE 60000   0 0 2023-04-17T18:06:02-04:00
2962971 CAPITOL COUNSEL LLC 31fd640c-ddbc-4843-ae02-52d606aaadc8 Q1 CAPITOL COUNSEL LLC 313715 EMD SERONO, INC. 2023 first_quarter PHA Issues regarding the availability and pricing of prescription drugs. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-04-17T21:25:23-04:00
2963005 CAPITOL COUNSEL LLC 2a92e498-9669-4864-a76e-2c13b1132569 Q1 CAPITOL COUNSEL LLC 313715 VERTEX PHARMACEUTICALS INCORPORATED 2023 first_quarter PHA Monitoring and advocacy on matters related to the pharmaceutical industry. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-04-17T22:15:08-04:00
2963151 ELI LILLY AND COMPANY fb33fc1e-5626-4c68-8a2d-09eb09e49b51 Q1 ELI LILLY AND COMPANY 13392 ELI LILLY AND COMPANY 2023 first_quarter PHA Hospital discounts; 340B program HOUSE OF REPRESENTATIVES,SENATE   1470000 0 0 2023-04-18T07:57:48-04:00
2963226 ASSOCIATION FOR ACCESSIBLE MEDICINES e3e3c44f-ada4-4240-bc15-eb44d4d0ff40 Q1 ASSOCIATION FOR ACCESSIBLE MEDICINES 16032 ASSOCIATION FOR ACCESSIBLE MEDICINES 2023 first_quarter PHA Prescription Drug Costs. Drug Pricing. Pre-Hatch-Waxman ANDAs (PANDAs). Civil Monetary Penalties. Pharmaceutical Exclusivity. 180-Day Exclusivity. Labeling of Generic Drugs and Biosimilars. Section 505(j)(10) Labeling [Legislation not yet introduced]. Generic Carveouts Patent Protected Information in Drug Labels Including Issues Related to GSK v. Teva. Generic Formulations. Incentivize Domestic Manufacturing. Drug Shortages. Stockpile of Generic Drugs. Generic Drug User Fee Amendments (GDUFA). GDUFA III Negotiations. BsUFA III Negotiations. Biosimilars Insulin. Cost Sharing for Biosimilars. Hybrid Biosimilar Applications [Legislation not yet introduced]. 505(b)(2) Biosimilar Proposal. Same Strength Requirement for Biosimilars. FDA Inspections. Energy & Commerce Factory Inspection Legislation. FDA-PTO Collaboration. FDA Genus Decision. FDA Catalyst Decision. Shaheen-Cassidy Citizen Petition Legislation. 506I Marketing Status Updates. Buy American Proposals. Issues Related to COVID-19. Inflation Reduction Act (IRA) Implementation. Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Economic Council (NEC),SENATE   480000 0 0 2023-04-18T08:48:45-04:00
2963487 RICCHETTI INCORPORATED b9eff7aa-04c5-4699-8b0f-793bf4e57a75 Q1 RICCHETTI INCORPORATED 62778 EISAI, INC. 2023 first_quarter PHA Issues related to coverage of Alzheimer's drugs and diagnostics under Federal health care programs; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement; Issues related to pharmaceutical industry, generally HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-04-18T10:19:36-04:00
2963517 RICCHETTI INCORPORATED 29dba94a-855b-47d4-99f2-1c11c453d64a Q1 RICCHETTI INCORPORATED 62778 HORIZON THERAPEUTICS USA INC 2023 first_quarter PHA Issues related to pharmaceutical industry, generally; Issues related to drug pricing and access, and Medicare and Medicaid reimbursement HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-04-18T10:23:36-04:00
2963532 RICCHETTI INCORPORATED 520f85e7-0e9c-41da-a4db-2b86fa9192c3 Q1 RICCHETTI INCORPORATED 62778 IPSEN BIOPHARMACEUTICALS, INC. 2023 first_quarter PHA Issues related to pharmaceutical industry, generally ssues related to development of products to treat limb spasticity and fibrodysplasia ossificans progressiva (FOP) HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-04-18T10:25:42-04:00
2963534 BUCHANAN INGERSOLL & ROONEY PC 371b1e73-db42-4437-ad94-a6fa9be6714a Q1 BUCHANAN INGERSOLL & ROONEY PC 55291 AIM IMMUNOTECH INC. 2023 first_quarter PHA Strategy development and implementation of company's federal government relations initiatives relating to research and development of therapeutics. Work with Department of Defense on Ebola countermeasures. Comprehensive Access to Resources and Education (CARE) For Long COVID Act Defense, Dept of (DOD),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 20000   0 0 2023-04-18T10:26:02-04:00
2963538 RICCHETTI INCORPORATED e343a154-9175-4cf7-ba89-450a74efb825 Q1 RICCHETTI INCORPORATED 62778 NEUROCRINE BIOSCIENCES, INC. 2023 first_quarter PHA Issues related to pharmaceutical industry, generally HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-04-18T10:26:33-04:00
2963734 CARD & ASSOCIATES, LLC b47e4680-61fb-4c3e-9849-0bbeb4b64ae3 Q1 CARD & ASSOCIATES, LLC 84217 AMAZON.COM (FRA PILLPACK AN AMAZON COMPANY) 2023 first_quarter PHA Monitor legislation and on drug price transparency and market access issues including legislative proposals related to drug pricing Monitor FY 2024 Appropriations Support access to telehealth HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-04-18T11:06:19-04:00
2963741 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH bd2881bd-9b4d-4a2b-80cf-51e4d8f33b56 Q1 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 401104060 THE MICHAEL J. FOX FOUNDATION FOR PARKINSON'S RESEARCH 2023 first_quarter PHA S.652 - Safe Step Act: a bill to require group health plans to provide an exception process for any medication step therapy protocol to help ensure that people living with Parkinson's disease can safely and efficiently access treatments. Increasing prescription drug affordability and accessibility for people living with Parkinson's via Medicare Part D redesign and benefits, including expanding the low-income subsidy (LIS) program, capping out-of-pocket costs, implementing a smoothing mechanism, and streamlining prior authorization processes Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2023-04-18T11:06:40-04:00
2963968 CAPITOL COUNSEL LLC 7a784a19-26c8-468e-a425-39951d60fd54 Q1 CAPITOL COUNSEL LLC 313715 PHARMAPOTHECA A, INC. 2023 first_quarter PHA Advocacy to encourage FDA to establish science-based limits to control contamination of a potential genotoxic trace impurity in amphetamine-based ADHD dosage forms. HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-04-18T11:45:29-04:00
2964172 BROWN & FORTUNATO, P.C. 94d9ad75-b7eb-4a09-9d0a-e65e9a8e8731 Q1 BROWN & FORTUNATO, P.C. 401104878 PROMPTCARE COMPANIES, INC. 2023 first_quarter PHA Issues related to Medicare home infusion therapy benefit and other health care issues. Issues related to the Medicare DMEPOS competitive bidding program and Medicare coverage and payment for non-invasive ventilators. Centers For Medicare and Medicaid Services (CMS) 10000   0 0 2023-04-18T12:22:07-04:00
2964509 KOUNTOUPES DENHAM CARR & REID, LLC c5ac2294-a044-4967-bc54-4205d86de63e Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 ABBOTT LABORATORIES 2023 first_quarter PHA Legislation to expand Medicare coverage to permanently include services provided by a pharmacist, including incidental services and supplies, related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses, including H.R. 7213, the Equitable Community Access to Pharmacist Services Act. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-18T13:42:33-04:00
2965115 RED+BLUE STRATEGIES 07411d40-fd38-4029-92fa-f64151c76e28 Q1 RED+BLUE STRATEGIES 400693064 COHERUS BIOSCIENCES 2023 first_quarter PHA Issues related to advancing biosimilars in the health care market place to increase access and efficacy of life saving drugs. Support for encouraging the development, manufacturing and distribution of American-made biosimilars and other related products. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-04-18T15:43:33-04:00
2965430 ARENTFOX SCHIFF LLP 17998653-6abb-4e0f-ab16-a02ca920870c Q1 ARENTFOX SCHIFF LLP 4208 AMERICAN PHARMACY COOPERATIVE, INC. 2023 first_quarter PHA Prescription drug pricing generally HOUSE OF REPRESENTATIVES,SENATE,White House Office 30000   0 0 2023-04-18T16:25:20-04:00
2965652 TWENTY-FIRST CENTURY GROUP, INC. a6f5e3fb-77d9-4b8c-9131-5705cf484f47 Q1 TWENTY-FIRST CENTURY GROUP, INC. 38687 CARDINAL HEALTH, INC. 2023 first_quarter PHA Issues related to the distribution and sale of pharmaceutical and medical products and services; medical and public health preparedness; COVID-19 pandemic response; and the healthcare supply chain. HOUSE OF REPRESENTATIVES,SENATE 24000   0 0 2023-04-18T16:57:01-04:00
2966026 BROWNSTEIN HYATT FARBER SCHRECK, LLP eb78f14a-be56-4bb7-bb99-035a8da80ff8 Q1 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 ROMARK GLOBAL PHARMA, LLC 2023 first_quarter PHA Issues regarding Biomedical Advanced Research and Development Authority Covid-19 Therapeutics' HOUSE OF REPRESENTATIVES,SENATE 110000   0 0 2023-04-18T18:22:52-04:00
2966509 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7ceaa7ae-a5bb-4bb9-8467-5360445cf655 Q1 BROWNSTEIN HYATT FARBER SCHRECK, LLP 7257 LILLY USA, LLC 2023 first_quarter PHA Issues related to the pharmaceutical industry Issues related to Inflation Reduction Act Implementation HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-18T23:45:22-04:00
2966705 BOLD STRATEGIES, LLC 3a91200a-4de7-4067-b02d-edcad823b626 Q1 BOLD STRATEGIES, LLC 401104653 MORRIS & DICKSON CO., LLC 2023 first_quarter PHA Prescription drug issues generally. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-04-19T08:37:52-04:00
2966706 KOUNTOUPES DENHAM CARR & REID, LLC 2bf04802-8d80-4700-a786-b46aeaa35c36 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CONSUMER HEALTHCARE PRODUCTS ASSOCIATION 2023 first_quarter PHA General issues related to over-the-counter pharmaceutical supply chain. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-04-19T08:38:54-04:00
2966749 KOUNTOUPES DENHAM CARR & REID, LLC 33a58608-9352-46d6-a44f-91db22ad4c48 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CVS HEALTH 2023 first_quarter PHA Issues related to pharmacies including legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies related to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-04-19T08:53:17-04:00
2966869 FAEGRE DRINKER BIDDLE & REATH LLP 5c97e429-f753-4619-a243-7df6c849cf57 Q1 FAEGRE DRINKER BIDDLE & REATH LLP 12631 ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP GLOBAL) 2023 first_quarter PHA Illicit prescription drug sales online; Rogue internet drug sellers; Dangers of counterfeit medicines; Risks of drug importation on patient safety; Domain name system accountability; S.3399, H.R. 6352 - Domain Reform for Unlawful Drug Sellers Act (DRUGS Act);S. 1843, H.R. 3429 - SHOPSAFE Act; S. 4858 - Cooper Davis Act. HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-04-19T09:22:33-04:00
2966874 FAEGRE DRINKER BIDDLE & REATH LLP a5b28ebe-10d2-4a22-97a7-dfbc39184bf4 Q1 FAEGRE DRINKER BIDDLE & REATH LLP 12631 EMPOWER PHARMACY 2023 first_quarter PHA Issues related to compounding medications, including safety and supply chain issues. HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-04-19T09:23:02-04:00
2967102 MEHLMAN CONSULTING, INC. 429558b6-a989-4735-adbc-16d6f2738280 Q1 MEHLMAN CONSULTING, INC. 284950 THE CAMPAIGN FOR SUSTAINABLE RX PRICING 2023 first_quarter PHA Prescription drug pricing issues. Pricing of Covid 19 vaccines. H.R. 485 - the Protecting Health Care for All Patients Act. Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-04-19T09:54:17-04:00
2967188 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 5f028448-d8bf-4639-abdd-ddb32b39ff41 Q1 NATIONAL ORGANIZATION FOR RARE DISORDERS, INC. (NORD) 28264 NATIONAL ORGANIZATION FOR RARE DISORDERS INC (NORD) 2023 first_quarter PHA Pharmaceutical issues impacting patients with rare diseases. Orphan Drug Act. Prescription Drug User Fee Act (PDUFA) Reauthorization. User Fee Agreements. Inflation Reduction Act Implementation. Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2023-04-19T10:03:03-04:00
2967220 UNIVERSITY OF IOWA 8a403bd0-f390-4027-bc89-1e9be69000d5 Q1 UNIVERSITY OF IOWA 49191 UNIVERSITY OF IOWA 2023 first_quarter PHA N/A HOUSE OF REPRESENTATIVES,SENATE   50000 0 0 2023-04-19T10:06:02-04:00
2967481 SQUIRE PATTON BOGGS 5b856e63-a6db-49cf-957c-4cfb8d982d7e Q1 SQUIRE PATTON BOGGS 30906 SK HYNIX AMERICA, INC. 2023 first_quarter PHA Monitor proposals and issues related to biopharmaceuticals. HOUSE OF REPRESENTATIVES,SENATE 200000   0 0 2023-04-19T10:28:28-04:00
2967682 VAN SCOYOC ASSOCIATES d9007232-9b4f-4865-97ac-8a18b3a31e8c Q1 VAN SCOYOC ASSOCIATES 39837 ZEBRA TECHNOLOGIES CORP. 2023 first_quarter PHA National Defense Authorization Act for Fiscal Year 2024, Temperature monitoring technology HOUSE OF REPRESENTATIVES 30000   0 0 2023-04-19T10:43:02-04:00
2967748 FAEGRE DRINKER BIDDLE & REATH LLP 6320b445-2a39-43c4-bcf8-67a0fa9b9dd8 Q1 FAEGRE DRINKER BIDDLE & REATH LLP 12631 NATIONAL ASSOCIATION OF BOARDS OF PHARMACY 2023 first_quarter PHA Medication safety, pharmacy regulation and licensure, drug supply chain security, and combatting the opioid epidemic; Prescription drug monitoring programs; HR 501 Block, Report, and Suspend Suspicious Shipments Act; Ryan Haight Act/DEA rule on telehealth. Drug Enforcement Administration (DEA),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),SENATE 30000   0 0 2023-04-19T10:48:25-04:00
2967976 FORBES-TATE b7e1b4ac-68ce-4ac9-ac9b-8c280333921c Q1 FORBES-TATE 400976792 PHRMA 2023 first_quarter PHA Issues pertaining to prescription drug pricing; Issues related to the implementation of H.R. 5376 - Inflation Reduction Act of 2022 (P.L. 117-169). HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-04-19T11:02:59-04:00
2968284 BURRELL INTERNATIONAL GROUP LLC 7ad9f799-4645-49e8-a690-b76ec301294c Q1 BURRELL INTERNATIONAL GROUP LLC 401103483 ACER THERAPEUTICS 2023 first_quarter PHA COVID-19 therapeutics and Medical Countermeasures, Rare Disease, and Re-purposed drugs; Defense Appropriations for MCM Development HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-04-19T11:30:07-04:00
2968442 BLUECROSS BLUESHIELD OF TENNESSEE 189d194b-0d11-4792-8916-7ab92a47cd6c Q1 BLUECROSS BLUESHIELD OF TENNESSEE 6440 BLUECROSS BLUESHIELD OF TENNESSEE 2023 first_quarter PHA Insulin Act; Insulin Out of Pocket Charges; Pharmacy Benefit Managers S 954 - Affordable Insulin Now Act A bill to provide for appropriate cost-sharing for insulin products covered under private health plans and to establish a program to support health care providers and pharmacies in providing discounted insulin products to uninsured individuals. HOUSE OF REPRESENTATIVES,SENATE   195000 0 0 2023-04-19T11:41:53-04:00
2968461 BURRELL INTERNATIONAL GROUP LLC 5c7712e7-fce9-4275-b0c7-f24641643fa3 Q1 BURRELL INTERNATIONAL GROUP LLC 401103483 TONIX PHARMACEUTICALS HOLDING CORP. 2023 first_quarter PHA LHHS Appropriation R&D Funding, Pandemic Preparedness Funding for Next Generation Products HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-04-19T11:43:02-04:00
2968479 WINNING STRATEGIES WASHINGTON e1997dae-0a51-4a50-aa33-e44336fb5a2d Q1 WINNING STRATEGIES WASHINGTON 50796 HEALTHCARE INSTITUTE OF NEW JERSEY 2023 first_quarter PHA Legislation related to extension of FDA user fees HOUSE OF REPRESENTATIVES,SENATE 10000   0 0 2023-04-19T11:44:57-04:00
2968503 BURRELL INTERNATIONAL GROUP LLC d6b18087-1dc2-4601-818e-761dd1670880 Q1 BURRELL INTERNATIONAL GROUP LLC 401103483 SHIONOGI INC. 2023 first_quarter PHA Pandemic preparedness; Antimicrobial resistance; Draft of proposed PASTEUR Act language (No bill numbers yet) HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-04-19T11:48:59-04:00
2968765 KOUNTOUPES DENHAM CARR & REID, LLC 017a58c5-e077-471e-bb83-a8ca93cd2be7 Q1 KOUNTOUPES DENHAM CARR & REID, LLC 320918 CENCORA INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) 2023 first_quarter PHA Issues related to the pharmaceutical supply chain, drug shortages, and national stockpiles, including H.R. 405, the Essential Medicines Strategic Stockpile Act of 2023. Legislation that would permanently provide Medicare coverage of services provided by a pharmacist, including incidental services and supplies relating to testing, drug regimens, and vaccines for COVID-19, influenza, and certain other illnesses. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-19T12:15:42-04:00
2969155 WINNING STRATEGIES WASHINGTON c1ce83a0-27ad-4743-b01c-9943e0cbad33 Q1 WINNING STRATEGIES WASHINGTON 50796 KALEO 2023 first_quarter PHA Pharmaceutical drug development, including epinephrine for anaphylaxis; drug access and affordability issues HOUSE OF REPRESENTATIVES,SENATE 30000   0 0 2023-04-19T13:01:45-04:00
2969641 CROSSROADS STRATEGIES, LLC d06c502c-14a7-47cc-a8d4-af5560b52f70 Q1 CROSSROADS STRATEGIES, LLC 400531586 INDIVIOR INC. 2023 first_quarter PHA Issues related to overdose reversal products; H.R.2617, Consolidated Appropriations Act, 2023 (P.L.117-328) implementation; FY2024 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations. HOUSE OF REPRESENTATIVES,SENATE 50000   0 0 2023-04-19T13:46:11-04:00
2969907 SHIONOGI INC. c526e3c1-dccf-4e75-8519-f67586955af2 Q1 SHIONOGI INC. 401107081 SHIONOGI INC. 2023 first_quarter PHA Pandemic preparedness; Antimicrobial resistance; Pandemic and All Hazards Preparedness Act (PAHPA) Reauthorization Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE   130000 0 0 2023-04-19T14:11:36-04:00
2970001 PORT SIDE STRATEGIES, LLC 144b5ed1-eb37-42d1-8a87-7bc80aa4b653 Q1 PORT SIDE STRATEGIES, LLC 401105394 NEW VENTURE FUND 2023 first_quarter PHA Issues related to implementation of the drug pricing provisions of the Inflation Reduction Act of 2022. HOUSE OF REPRESENTATIVES,SENATE     0 0 2023-04-19T14:17:25-04:00
2970028 FAMILIES USA FOUNDATION, INC. 0980ede3-1969-406d-a5c3-2e085c101934 Q1 FAMILIES USA FOUNDATION, INC. 14108 FAMILIES USA FOUNDATION INC 2023 first_quarter PHA S.113Prescription Pricing for the People Act of 2023To require the Federal Trade Commission to study the role of intermediaries in the pharmaceutical supply chain and provide Congress with appropriate policy recommendations, and for other purposes. s.150Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. HOUSE OF REPRESENTATIVES,SENATE     0 0 2023-04-19T14:19:01-04:00
2970113 CORNERSTONE GOVERNMENT AFFAIRS, INC. b8acb6c6-136b-48ee-929c-8a46b6ddab48 Q1 CORNERSTONE GOVERNMENT AFFAIRS, INC. 75557 CHILDREN'S NATIONAL MEDICAL CENTER 2023 first_quarter PHA Health-related issues including reimbursement, research, public-health & clinical care. Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE 50000   0 0 2023-04-19T14:24:36-04:00
2970161 PRIME POLICY GROUP f3d4baca-93bf-47fc-ac98-da4ced23d415 Q1 PRIME POLICY GROUP 400532589 NATIONAL ASSOCIATION OF CHAIN DRUG STORES 2023 first_quarter PHA H.R. 1770 - Equitable Community Access to Pharmacist Services Act; PBM reform; PREP Act authorities HOUSE OF REPRESENTATIVES,SENATE,White House Office 60000   0 0 2023-04-19T14:27:45-04:00
2970257 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS e014a05c-e9d8-497e-a6a1-1fc1d1907005 Q1 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 3457 AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS 2023 first_quarter PHA Issues related to FDA authority to manage drug shortages, regulation of pharmacy compounding, and implementation of the Drug Quality and Security Act. Issues related to COVID-19 response recommendations (generally, no specific legislation). The Protect 340B Act (H.R. 2534), provisions related to enforcement of the 340B Drug Pricing Program. Issues related to the rollout of Test to Treat Programs (generally, no specific legislation). Issues related to pharmacy residency funding (generally, no specific legislation). Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE   220000 0 0 2023-04-19T14:35:03-04:00
2970860 E3 STRATEGIC CONSULTING GROUP c593a642-9c9d-45a2-927b-fe2a4bdee017 1T E3 STRATEGIC CONSULTING GROUP 401104104 HEINZ STRATEGIES LLC (ON BEHALF OF PILMA) 2023 first_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023. HOUSE OF REPRESENTATIVES,SENATE     0 1 2023-04-19T15:26:11-04:00
2970882 E3 STRATEGIC CONSULTING GROUP b7e1d6d7-8737-4723-853e-df0e19a61c76 Q1 E3 STRATEGIC CONSULTING GROUP 401104104 PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION 2023 first_quarter PHA Prescription drug industry issues relating to domestic construction and maintenance, prescription drug pricing, and employment issues, generally; S.127 - Pharmacy Benefit Manager Transparency Act of 2023; S.113 - Prescription Pricing for the People Act of 2023 HOUSE OF REPRESENTATIVES,SENATE 20000   0 0 2023-04-19T15:28:12-04:00
2971112 POLARIS GOVERNMENT RELATIONS, LLC a96146b5-4c5c-400f-b760-85902ae6c44d Q1 POLARIS GOVERNMENT RELATIONS, LLC 307730 CIGNA CORPORATION 2023 first_quarter PHA Drug pricing and issues facing the pharmacy benefit manager industry generally HOUSE OF REPRESENTATIVES,SENATE 90000   0 0 2023-04-19T15:43:45-04:00
2971312 AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES 7c9e503f-23bd-4eab-af01-4af7b918c865 Q1 AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES 2321 AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES 2023 first_quarter PHA S 1139- Lowering the Price of Prescription Drugs HOUSE OF REPRESENTATIVES,SENATE   490000 0 0 2023-04-19T15:53:36-04:00
2972368 HEALTHSPERIEN 6d2a1eb8-c5d9-44ac-9965-967ce0e21a48 Q1 HEALTHSPERIEN 401103150 EXACT CARE PHARMACY 2023 first_quarter PHA Advocate for codifying definition for long-term care pharmacy. (S. 1574) Advocate for inclusion of chronic care pharmacy in CMS and CMMI payment approaches Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-04-19T17:21:16-04:00
2972820 INVARIANT LLC 26fe8d4b-47d0-4962-b412-c17181a02745 Q1 INVARIANT LLC 314237 SK HYNIX AMERICA INC. 2023 first_quarter PHA Monitor proposals and issues related to biopharmaceuticals. Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE 140000   0 0 2023-04-19T18:07:24-04:00
2973062 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 4c05cc3e-3f31-416e-bfa7-ef51e4964bd2 Q1 BLUE CROSS AND BLUE SHIELD OF KANSAS, INC. 323876 BLUE CROSS AND BLUE SHIELD OF KANSAS INC 2023 first_quarter PHA INSULIN Act; Insulin Out of Pocket Charges; S. 148 - Stop STALLING Act Sponsor: Sen. Amy Klobuchar (D-MN) S. 142 - Preserve Access to Affordable Generics and Biosimilars Act Sponsor: Sen. Amy Klobuchar (D-MN) S. 150 - Affordable Prescriptions for Patients Act of 2023 Sponsor: Sen. John Comyn (R-TX) S. 127 - Pharmacy Benefit Manager Transparency Act of2023 Sponsor: Sen. Maria Cantwell (D-WA) S. 954 - Affordable Insulin Now Act of 2023 Sponsor: Sen. Raphael Warnock (D-GA) Centers For Medicare and Medicaid Services (CMS),SENATE     0 0 2023-04-19T18:40:24-04:00
2973144 KING & SPALDING LLP c0715f23-abe0-41bc-8a6d-7442a52960c8 Q1 KING & SPALDING LLP 21632 SUMITOMO PHARMA AMERICA (FORMERLY SUNOVION PHARMACEUTICALS, INC.) 2023 first_quarter PHA Advocacy on low income subsidy benefits HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-19T18:59:21-04:00
2973199 TARPLIN, DOWNS & YOUNG, LLC 69a07c2c-8470-4eef-b6fb-7f8e1c083995 Q1 TARPLIN, DOWNS & YOUNG, LLC 304736 ASTRAZENECA 2023 first_quarter PHA IRA implementation, drug coverage and reimbursement, drug shortages, supply chain integrity, innovation, transparency, 340B HOUSE OF REPRESENTATIVES,SENATE 80000   0 0 2023-04-19T19:18:26-04:00
2973210 DESIMONE CONSULTING, LLC b0fb6e75-fa88-4873-ab20-892c27012708 Q1 DESIMONE CONSULTING, LLC 400931695 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) 2023 first_quarter PHA Issues related to patient access and pricing. Issues related to policy changes to Medicare Part D. Issues related to PBM reform. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-04-19T19:20:47-04:00
2973492 MARSHALL & POPP, LLC 2a123ed9-82f0-4077-8a9e-d314107e6d31 Q1 MARSHALL & POPP, LLC 401105121 AMGEN USA INC. 2023 first_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S.127, Pharmacy Benefit Manager Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-19T20:41:16-04:00
2973671 MARSHALL & POPP, LLC d017204a-7fd0-402f-bd5f-ed10dc959cfb Q1 MARSHALL & POPP, LLC 401105121 GENENTECH, INC. 2023 first_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to 340B. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-19T21:25:25-04:00
2973704 WEST FRONT STRATEGIES LLC 11880880-cc49-4ab0-88ca-dcdfd2b6b8fe Q1 WEST FRONT STRATEGIES LLC 401103493 FRESENIUS KABI USA LLC 2023 first_quarter PHA Issues related to drug pricing; issues related to Biosimilars; issues related to competition. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-04-19T21:29:55-04:00
2973709 MARSHALL & POPP, LLC 14d37ae9-f9c5-4c49-86d2-792c3bee7295 Q1 MARSHALL & POPP, LLC 401105121 PFIZER, INC. 2023 first_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to 340B. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-19T21:30:44-04:00
2973713 MARSHALL & POPP, LLC d5c4910e-ad30-4d6d-91d9-5d609a3d100f Q1 MARSHALL & POPP, LLC 401105121 PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA 2023 first_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development and distribution. Issues related to 340B. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 40000   0 0 2023-04-19T21:31:45-04:00
2973720 MARSHALL & POPP, LLC dfa09439-7e39-4b53-a490-d50e6d479018 Q1 MARSHALL & POPP, LLC 401105121 SANOFI U.S. SERVICES, INC. 2023 first_quarter PHA Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169). Issues related to vaccine development, distribution and injury compensation. Issues related to 340B. Issues related to insulin pricing. Issues related to FDA regulation of pharmaceuticals. Issues related to prescription drug pricing and pharmacy benefit manager business practices, including S. 127, Pharmacy Benefit Manager Transparency Act. HOUSE OF REPRESENTATIVES,SENATE 60000   0 0 2023-04-19T21:32:51-04:00
2973812 WEST FRONT STRATEGIES LLC 88ceccf7-4da2-4457-99fd-b459f8c46d1c Q1 WEST FRONT STRATEGIES LLC 401103493 VIATRIS INC 2023 first_quarter PHA Issues related to e-labeling; monitor issues related to Pharmacy Benefit Manager Transparency Act, S.127. HOUSE OF REPRESENTATIVES,SENATE 70000   0 0 2023-04-19T22:01:05-04:00

Next page

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE lobbying_activities (
            id INTEGER PRIMARY KEY,
            filing_uuid TEXT NOT NULL,
            filing_type TEXT NOT NULL,
            registrant_name TEXT NOT NULL,
            registrant_id INTEGER,
            client_name TEXT NOT NULL,
            filing_year INTEGER NOT NULL,
            filing_period TEXT NOT NULL,
            issue_code TEXT,
            specific_issues TEXT,
            government_entities TEXT,
            income_amount INTEGER,
            expense_amount INTEGER,
            is_no_activity INTEGER DEFAULT 0,
            is_termination INTEGER DEFAULT 0,
            received_date TEXT,
            CONSTRAINT fk_activity_filing FOREIGN KEY (filing_uuid)
                REFERENCES lobbying_filings_raw(filing_uuid)
        );
CREATE INDEX idx_act_client_name ON lobbying_activities(client_name COLLATE NOCASE);
CREATE INDEX idx_act_issue_code ON lobbying_activities(issue_code);
CREATE INDEX idx_act_filing_year ON lobbying_activities(filing_year);
CREATE INDEX idx_act_filing_uuid ON lobbying_activities(filing_uuid);
Powered by Datasette · Queries took 1917.481ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API